# Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

> **NCT02316899** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 500 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Constipation (IBS-C)

## Interventions

- **DRUG:** linaclotide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02316899
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-21
- **Primary completion:** 2015-09-19
- **Final completion:** 2016-03-29
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02316899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02316899, "Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02316899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*